Welcome to our dedicated page for PERKINELMER news (Ticker: PKI), a resource for investors and traders seeking the latest updates and insights on PERKINELMER stock.
PerkinElmer Inc. (symbol: PKI) is a leading global provider of solutions that enable scientists, researchers, and clinicians to tackle complex challenges in science and healthcare. The company's mission is to innovate for a healthier world through unique solutions that serve the diagnostics, life sciences, food, and applied markets.
PerkinElmer collaborates closely with its customers to deliver earlier and more accurate insights. This is supported by the company's deep market knowledge and technical expertise. With a dedicated workforce of approximately 14,000 employees worldwide, PerkinElmer is committed to improving the quality of life, creating healthier families, and sustaining the wellbeing and longevity of people globally.
In 2020, PerkinElmer reported revenues of approximately $3.8 billion and serves customers in 190 countries. Notably, the company is a component of the S&P 500 index, underscoring its significant market presence and financial stability.
Recent Achievements and Current Projects
- Strategic partnerships with key industry players to enhance diagnostic solutions and life sciences research.
- Continuous investment in innovative technologies and solutions that drive earlier and more accurate healthcare insights.
- Expansion of global reach through new product launches tailored to various market needs.
PerkinElmer's commitment to innovation and collaboration makes it a crucial player in the healthcare and scientific research sectors. By leveraging its extensive expertise and comprehensive solutions, the company strives to address the most pressing challenges faced by its customers.
PerkinElmer, Inc. (NYSE: PKI) will present at the Barclays Global Healthcare Conference on March 10, 2021, from 9:45 a.m. to 10:10 a.m. ET. The presentation will feature Prahlad Singh, president and CEO, discussing the Company's strategic priorities. Investors can access a live audio webcast of the event on PerkinElmer's website, with a replay available for 90 days post-event. In 2020, PerkinElmer reported revenues of approximately $3.8 billion, employs over 14,000 people, and serves clients in 190 countries, being part of the S&P 500 Index.
PerkinElmer (NYSE: PKI) has launched its COVID-19 Antigen Test for the qualitative detection of SARS-CoV-2 antigen, yielding results in 15 minutes. This test, suitable for professional use in various settings, is already available in over 30 countries. Clinical studies show a sensitivity rate exceeding 97% and 100% specificity, indicating no false positives. The company emphasizes the need for reliable antigen testing to support reopening strategies globally. The test complements PerkinElmer's existing portfolio, which includes high throughput RNA extraction and RT-PCR solutions.
PerkinElmer (NYSE: PKI) provided an update on the accreditation of its COVID-19 Valencia Branch Laboratory (VBL) in collaboration with the California Department of Public Health. The VBL commenced operations on November 1, 2020, and has capacity for 100,000 tests daily. Following a recent inspection, PerkinElmer addressed identified deficiencies and expects a positive response from the College of American Pathologists (CAP) accreditation. The laboratory has tested over 1.5 million samples. PerkinElmer emphasizes its commitment to quality and transparency throughout the accreditation process.
PerkinElmer, a leading global innovator, will present at the 41st Annual Cowen Health Care Conference on March 1, 2021, from 12:20 to 12:50 p.m. ET. CEO Prahlad Singh will discuss the company's strategic priorities. A live audio webcast will be available on the company's Investors page, with a replay accessible for 90 days after the event. In 2020, PerkinElmer reported approximately $3.8 billion in revenue and employs over 14,000 people across 190 countries, contributing to the S&P 500 Index.
PerkinElmer reported strong financial results for Q4 and the full year 2020. Q4 GAAP earnings per share were $3.38, up from $0.58 in Q4 2019. Revenue climbed to $1.355 billion from $805 million YoY. The full year saw GAAP EPS of $6.50, compared to $2.04 in 2019, with annual revenue reaching $3.783 billion, up from $2.884 billion. The Diagnostics segment thrived, with Q4 revenue up 176% to $852 million. For 2021, the company forecasts GAAP revenue of at least $4.08 billion and EPS of at least $6.73, reflecting continued growth.
The Board of Directors of PerkinElmer (NYSE: PKI) announced a quarterly dividend of $0.07 per share, payable on May 7, 2021. Shareholders on record as of April 16, 2021 will receive this dividend. PerkinElmer, a leader in health innovation, reported revenues of approximately $2.9 billion in 2019 and employs around 14,000 people globally, serving customers in 190 countries. The company is also a component of the S&P 500 Index.
PerkinElmer (NYSE:PKI) announced that its New Coronavirus Nucleic Acid Detection Kit has received Emergency Use Authorization (EUA) from the FDA for testing asymptomatic individuals. A significant finding indicates that nearly 60% of COVID-19 transmissions originate from asymptomatic carriers, highlighting the need for effective diagnostic testing. This test boasts the lowest Limit of Detection among authorized COVID-19 tests, making it highly sensitive. The company also offers sample pooling options, enhancing testing capabilities without additional resources.
PerkinElmer (NYSE: PKI) projects 66% reported and 63% organic revenue growth for Q4 2020, with GAAP EPS of at least $2.88 and adjusted EPS of at least $3.60. This robust performance is mainly due to increased demand for COVID-19 solutions, generating approximately $535 million in revenue. However, the non-COVID-19 segment saw a 3% organic decline. The financial results will be released on February 2, 2021, followed by a conference call at 5:00 p.m. ET.
PerkinElmer will acquire Oxford Immunotec for $22.00 per share, valuing the deal at approximately $591 million. This acquisition, expected to close by mid-2021, represents a premium of 28.3% compared to Oxford Immunotec's last closing price and significantly enhances PerkinElmer's portfolio in infectious disease testing, particularly for tuberculosis. PerkinElmer anticipates the deal to be modestly accretive to earnings in the first year and expects Oxford Immunotec's sales growth to outpace its own Diagnostics franchise. Oxford Immunotec will become a privately held company post-acquisition.
PerkinElmer (NYSE: PKI) has announced its participation in the J.P. Morgan Healthcare Conference on January 11, 2021, at 7:30 a.m. ET. CEO Prahlad Singh will present updates on the company’s strategic priorities. The presentation will be accessible via a live audio webcast on PerkinElmer's investor relations website, with a replay available for 90 days post-event. In 2019, PerkinElmer generated approximately $2.9 billion in revenue and operates globally with about 14,000 employees.
FAQ
What is the market cap of PERKINELMER (PKI)?
What does PerkinElmer Inc. do?
What is the mission of PerkinElmer Inc.?
How many employees does PerkinElmer Inc. have?
What was PerkinElmer Inc.'s revenue in 2020?
In how many countries does PerkinElmer Inc. serve customers?
What are some of PerkinElmer Inc.'s recent achievements?
How does PerkinElmer Inc. contribute to healthcare?
Is PerkinElmer Inc. part of any major stock index?
What markets does PerkinElmer Inc. serve?
What is a core focus of PerkinElmer Inc.'s partnerships?
